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Background: While nuts and their related nutrients have been inversely associated with some 
cancers, the association between nut consumption and prostate cancer has been inconsistent.  
Methods: We conducted an analysis of the association between nut and peanut butter 
consumption and risk of incident prostate cancer among 173,243 men in the prospective NIH-
AARP Diet and Health Study. There was a total of 18,619 incident prostate cancer cases during 
the 16 years of follow-up. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) 
using Cox proportional hazards regression for intake of nuts, peanut butter, and total nuts (nuts 
plus peanut butter), as well as frequency of nut consumption. We evaluated associations with 
overall prostate cancer and the following subtypes: adenocarcinoma, localized, advanced, fatal, 
low-grade (Gleason 2-7), and high-grade (Gleason ≥8). 
Results: There was no association between nuts (highest versus lowest category HR=1.00, 95% 
CI: 0.95, 1.07), peanut butter consumption (HR=1.02, 95% CI: 0.98, 1.07), or total nuts 
(HR=1.00, 95% CI: 0.93, 1.09) and prostate cancer. Similarly, there were no associations with 
nuts, peanut butter, and total nuts localized, advanced, or fatal prostate cancer in this population. 
There was some evidence of an inverse association for frequency of nut consumption and 
prostate cancer (highest versus lowest category HR=0.93, 95% CI: 0.88, 0.98), but the p-trend 
was not statistically significant (0.07). 
Conclusions:  In this large prospective cohort study, there was no clear evidence for an 
association between nut or peanut butter consumption and prostate cancer. Additional research in 
prospective studies with detailed information on nut consumption is warranted given the lack of 
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Prostate cancer is the second most common cancer among men worldwide and the 
leading cancer among US men. In 2018, the US had over 170,000 new prostate cases, accounting 
for almost 1 in 5 new male cancer diagnoses [1]. A recent review of dietary risk factors in 
relation to prostate cancer did not find evidence to place nut consumption as a clear risk factor or 
as a protective factor [2]. However, nuts have been hypothesized to be associated with a 
decreased risk of cancer through multiple mechanisms [2, 3].  
Nuts are nutrient dense foods that are rich in important macronutrients and bioactive 
compounds, such as unsaturated fatty acids (MUFAs and PUFAs), high-quality vegetable 
protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds [4, 5]. The nutrients 
in nuts may modify specific processes related to cancer development, such as the regulation of 
cell differentiation and proliferation, reduction of tumor initiation or promotion, DNA protection, 
and regulation of immunologic inflammatory responses [4]. Specifically, flavonoids metabolize 
and facilitate the elimination of potentially cancerous chemical compounds or their metabolites, 
while antioxidant micronutrients may protect against oxidative damage [4, 6]. In vitro data also 
suggests that antioxidant micronutrients protect biomolecules that can influence the risk for 
cancer development [4, 6]. Additional nutrients found in nuts have other cancer preventative 
effects, such as polyphenols which inhibit chemically induced carcinogenesis, folic acid which 
reduces DNA damage, and resveratrol which regulates inflammatory response and 
immunological activity [7]. Numerous experimental studies in animals and cultures of cell lines 
have also indicated that vitamin E, a micronutrient found in high amounts in nuts, can regulate 
differentiation and proliferation [6].  
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Epidemiologic studies have found inverse associations between nut consumption and risk 
of gastric, esophageal, and lung cancers [8, 9]. Nut consumption has also been associated with a 
reduced risk of cancer incidence, cancer death, and all-cause mortality [7, 10]. For prostate 
cancer, a cross-national study found that prostate cancer mortality was inversely associated with 
the consumption of nuts and oilseeds [3]. Two previous case-control studies indicated that 
increasing nut consumption was inversely associated with prostate cancer; yet, the studies did not 
include consumption on nut butters [11, 12]. However, two prospective cohort studies in the 
Health Professionals Follow-up Study found no such association [13, 14]. Based on the limited 
research on this topic, in this study we examined nut and nut butter consumption in relation to 
prostate cancer risk in the prospective National Institutes of Health (NIH)-AARP Diet and 
Health Study cohort. 
 
MATERIALS AND METHODS 
Study Population 
The NIH-AARP Diet and Health Study is a prospective cohort study established in 1995 
to 1996 [15]. The cohort enrolled US adults between the ages of 50 and 71 years residing in six 
states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and two 
metropolitan areas (Atlanta, GA, and Detroit, MI). The self-administered baseline questionnaire 
(BQ) and risk factor questionnaire (RFQ) assessed demographics, lifestyle, and medical 
characteristics. The NIH-AARP Diet and Health Study was approved by the Special Studies 
Institutional Review Board of the US National Cancer Institute, and all participants provided 
written informed consent. 
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A total of 566,407 participants satisfactorily completed the BQ after excluding additional 
withdrawals (n=1), duplicate records (n=179), subjects who moved out of study area before 
returning BQ (n=321) or were found to have died before study entry (n=261). The RFQ was 
mailed to BQ participants without baseline self-reported colon, breast, or prostate cancers for 
additional epidemiologic info in 1996 to 1997. A total of 334,905 participants completed the 
RFQ after accounting for participants who withdrew from the study (n=3), died (n=1,619), or 
moved out of the study area (n=547) before the RFQ. For this analysis, women (n=161,432) 
were omitted leaving a population of 175,644 men who satisfactorily completed both the BQ and 
RFQ. Further removal of those with follow-up time of less than 0.05 years (n=2,401) left 
173,243 men. Finally, after excluding those who did not provide information on nut (n=2,064) 
and nut butter (n=1,720) intake, the final analytic populations included 171,179 and 171,523 men 
for the two dietary exposures, respectively.  
 
Assessment of Dietary Factors 
At baseline, participants completed a validated 124-item food-frequency questionnaire 
regarding dietary intake over the previous 12 months. [16]. Participants were asked how often 
they consumed nuts or nut butter, with regard to both portion size and frequency. Nut 
consumption was defined as “peanuts, walnuts, seeds, or other nuts” measured in one-fourth cup 
increments and peanut butter consumption was defined as “peanut butter or other nut butter” 
measured in tablespoon increments. The frequency categories ranged from never to ≥2 times per 
day, while portion sizes were less than ¼ cup to more than ½ cup for nuts and less than 1 
tablespoon to more than 2 tablespoons for nut butter. We used the following USDA conversions 
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from grams for nuts and nut butter: quarter cup of nuts equal to 32.7 grams and one tablespoon 
of nut butter equal to 16 grams.  
 
Ascertainment of Prostate Cancer and Cohort Follow-up 
Cancer registry linkages from eight states (California, Florida, Louisiana, New Jersey, 
North Carolina, Pennsylvania, Georgia, and Michigan) were conducted to obtain cancer 
diagnosis information. The analyses in the study were completed for the following categories of 
incident prostate cancer: overall, adenocarcinoma, localized, advanced, fatal, low-grade (Gleason 
2-7), and high-grade (Gleason ³8). Overall incident prostate cancer (n=18,619) was defined by 
registry confirmation, Surveillance, Epidemiology and End Results (SEER) mid-level detail 
cancer site group of first registry reported cancer, and SEER cancer site code in accordance with 
the International Classification of Diseases for Oncology (ICD-O-3). The cancer endpoint is 
defined as carcinoma in situ via the cancer registry, 26 in the SEER cancer site group of first 
registry, C619 in the ICD-O-3 cancer site group, and 28010 in the SEER cancer site recode in 
ICD-O-3. Localized prostate cancer was defined as stage T1 or T2, N0, M0 and Gleason score of 
2-7 at diagnosis (n=1,590) while advanced prostate cancer was defined as stage T3 or T4, N1, 
M1, or Gleason score of 8 or more at diagnosis (n=2,502). Fatal cancer was defined as those with 
a cause of death listed as prostate cancer death in the NDI (n=738). 
Participants from the NIH-AARP Diet and Health Study were followed from the return of 
the RFQ until diagnosis, death, relocation outside the registry ascertainment area, or December 
31, 2011. Changes in address through linkage were assessed with the US Postal Service, while 
vital status were assessed through the National Death Index (NDI) and Social Security 
Administration (SSA).  
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Statistical Analysis 
Cox proportional hazards regression models were used to estimate the hazard ratios 
(HRs) and 95% confidence intervals (95% CI) between nut and nut butter consumption and 
prostate cancer incidence. Person-years was used as the underlying time metric and was 
computed from the date of receiving a valid RFQ until the date of cancer diagnosis, death, 
relocation outside ascertainment area, or follow-up end (December 31, 2011), whichever 
occurred first. Using the Cox regression model and Kaplan-Meier curves, we evaluated the 
proportional hazards assumption. 
 Dietary variables were energy-adjusted using the multivariate nutrient dense method. 
Categorical cut-points for nut, peanut butter, and total nut (nut plus peanut butter) consumption 
were based on intake in the analytic cohort, with the first category serving as the referent. The 
first category contained non-consumers while the other three categories are based on tertiles of 
consumption of nut or peanut butter consumption among consumers of each of these foods. The 
median of each category was used to evaluate linear trend. We also assessed the association 
using continuous intake measures (1/4 cup for nut consumption and 1 tablespoon for nut butter 
consumption). Finally, we examined the association between frequency of nut and peanut butter 
consumption in relation to prostate cancer. Categorical cut-points were based on the FFQ 
categories (never to 1-6 times per year, 7-11 times per year to 1 time per month, 2-3 times per 
month to 1-2 times per week, and 3-4 times per week to 2+ times per day). 
We calculated HRs and 95% CI for age-adjusted and multivariate-adjusted models. Our 
multivariate models included age, vegetable intake, fruit intake, body mass index (BMI), 
calories, alcohol consumption, education level, smoking status, physical activity, race, self-
reported health status, cardiovascular disease, diabetes, marriage status, prostate cancer screening 
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history, and family prostate cancer history. We also evaluated the Healthy Eating Index 2010 
(HEI 2010), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids intake, 
multivitamin use, fiber, dairy, history of stroke, red meat consumption, height, calcium, beta-
carotene, alpha-tocopherol, selenium, supplement vitamin D, vitamin D, supplement vitamin E, 
and vitamin E as potential confounders, but as these variables did not alter risk estimates by 10% 
or more, they were not included in the final multivariate model.   
 To assess the potential for reverse causality, we conducted a sensitivity analysis in which 
we removed the first two years of follow-up. We also evaluated interactions between nut 
consumption and age, BMI, race, education, and prostate cancer screening status with likelihood 
ratio tests. The statistical significance cutoff for the interaction likelihood ratio test was a P-value 
of <0.05. 
All statistical analyses were performed using SAS software (Version 9.4). All P-values 
were 2-sided, and a P-value of <0.05 was considered statistically significant.  
 
RESULTS 
Our population had a median follow-up time of 15.0 (IQR=8.1-15.1) years. The median 
age of 173,243 males in our analytic sample was 63.7 (IQR=58.9-67.4) years, with 93.6% 
identifying as non-Hispanic white. The mean nut and peanut butter intake among consumers 
were 3.4 ± 9.3 and 3.7 ± 8.7 grams per day, respectively. The correlation between nut and peanut 
butter consumption was 0.09 (p-value <0.0001).  
As shown in Table 1, in general those with higher nut consumption were more likely to 
drink more alcohol, have a higher level of education, be more active, eat more meat, consume 
more calories, and have higher MUFA and PUFA intake compared to those with low nut 
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consumption. They were also less likely to smoke or to have a history of cardiovascular disease, 
diabetes, heart disease, and hypertension. Those who consumed more peanut butter were more 
likely to drink less alcohol, eat more meat, and have higher MUFA and PUFA intake.  
The associations between nut consumption and risk of prostate cancer are shown in Table 
2. In our fully adjusted models, there was no association between nut consumption and overall 
prostate cancer (highest versus lowest category HR=1.00, 95% CI: 0.95, 1.07). Similarly, no 
statistically significant associations between nut consumption and risk of localized, advanced, or 
fatal prostate cancer were observed. 
The associations between peanut butter consumption and risk of prostate cancer are 
shown in Table 3. We did not observe any statistically significant associations between peanut 
butter consumption and risk of overall prostate cancer (highest versus lowest category HR=1.02, 
95% CI: 0.98, 1.07) or for risk of the subtypes of prostate cancer we evaluated.  
Total nut intake (nut and peanut butter) and risk of prostate cancer is summarized in 
Table 4. We did not observe an association between total nut intake, and overall prostate cancer 
(highest versus lowest category HR=1.00, 95% CI: 0.94, 1.09). There was an inverse association 
between total nut intake for the top category of nut consumption compared to no nut intake and 
localized prostate cancer (HR: 0.77, 95% CI: 0.60, 0.99). However, the p-trend was not 
statistically significant (p-trend=0.36). There was also no association between total nut intake 
and risk of advanced or fatal prostate cancer. 
Nut consumption frequency was inversely associated with risk of overall prostate cancer 
for the higher versus the lowest category (HR: 0.93, 95% CI: 0.88, 0.98), with a borderline 
statistically significant p-trend (0.07) (Table 5). There was no association between nut frequency 
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and any of the prostate cancer subtypes. We also assessed absolute nut intake in which nut intake 
was not energy adjusted and found no statistically significant associations (data now shown).  
To account for reverse causality, the association between nut and peanut butter intake, 
and risk of prostate cancer was examined after exclusion of the first two years of follow-up 
(Supplemental Table 1). This sensitivity analysis did not alter the results. 
There were no statistically significant interactions with age, BMI, race, screening status, 
education attainment, and family history of prostate cancer, and nut intake (data not shown).  
 
DISCUSSION 
In this large prospective cohort study, we did not observe an association between nut and 
peanut butter intake and risk of overall prostate cancer. There was limited evidence of an inverse 
association with the highest category of total nuts and localized prostate cancer as well as the 
highest level of nut consumption frequency and overall prostate cancer, but the linear trends 
were not statically significant for both of these measures of nut consumption. To our knowledge, 
this study is the largest prospective study to examine the association for nuts and peanut butter in 
relation to overall prostate cancer and by prostate cancer subtypes. 
Previous studies have found an inverse association between nut consumption and other 
cancers including gastric, esophageal, and lung [8, 9]. However, inconsistent results have been 
observed for prostate cancer. An analysis that combined three case-control studies in Canada 
found that increasing intake of combined beans, lentils, and nuts was inversely associated with 
risk of prostate cancer (OR: 0.69; 95% CI: 0.53-0.91) [11]. Given that nuts were combined with 
other foods in this study, the results are difficult to compare to other studies. In another case-
control study in Canada, nut intake greater than 3.0 grams a day associated with decreased 
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prostate cancer risk (OR: 0.43; 95% CI: 0.22-0.85) [12]. It is important to consider that these 
case-control studies are potentially subject to recall bias. Our largely null results align with two 
prior prospective studies among Adventist men in California [14] and men in the Health 
Professionals Follow-up Study [13]. The study of Adventist men was limited by a small number 
of cases (n=180) and both of these existing cohort studies evaluated intake as frequency of nut 
consumption only and did not include nut butters. 
We did observe some limited evidence of an inverse association with the highest level of 
total nuts and localized prostate cancer, and most frequent nut consumption category and overall 
prostate cancer. However, for each of these associations, there was no statically significant linear 
trend. While we did not evaluate this in the present study, there are some data to support an 
inverse association between nut consumption after prostate cancer diagnosis and all-cause 
mortality from the Health Professionals Follow-Up Study [17]. Nut consumption has also been 
associated with a reduced risk of overall cancer incidence and cancer death, and all-cause 
mortality [7, 10]. 
There are multiple hypotheses surrounding potential anticancer properties of nuts. 
Growing evidence of the role of inflammation and oxidative stress in the development of specific 
cancer types point toward antioxidative and anti-inflammatory properties of nuts as a mechanism 
[18]. In vitro data has shown that antioxidant micronutrients may protect against oxidative 
damage thereby impacting cancer development [6]. Other nut phytochemicals have also been 
shown to have anticancer properties. Resveratrol induces apoptosis, inhibits cell invasion, and 
angiogenesis in in vivo models for breast, colorectal, liver, pancreatic, and prostate cancer 
through the inhibition of molecular targets [18, 19]. Phytoestrogens also act as estrogen 
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antagonists that may have protective action in hormone-dependent diseases, including prostate, 
breast, and bowel cancer [18]. 
The strengths of this study include the large sample size, prospective design, and long 
follow-up time that increased our power to detect even modest associations. We also had 
extensive data on dietary and lifestyle factors to assess for potential confounders. Our data on nut 
consumption included both frequency and portion size, and included questions on nuts as well as 
peanut butter. Furthermore, we had detailed disease data to be able to evaluate total prostate as 
well as prostate cancer subtypes. Further strengths include no recall bias, which may explain 
some of the differences between the cohort and case-control findings pertaining to this 
association, and the ability to assess reverse causality.  
Our study also had some limitations. We only had dietary data from one timepoint, so we 
could not assess the impact of changes in nut consumption over time. While our models 
accounted for numerous potential confounders, residual confounding might still be present. The 
generalizability of the cohort is also limited as the majority of the NIH-AARP study is non-
Hispanic white. Furthermore, while the FFQ was expansive, it did not ask participants to report 
on different types of nuts separately. In addition, FFQs are subject to nondifferential 
misclassification which may have biased our results toward the null.  
In conclusion, nut and peanut butter consumption were not clearly associated with 
prostate cancer risk in this large prospective cohort. Additional prospective studies with detailed 
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TABLE 1 Baseline characteristics of participants by categories of dietary nut and peanut butter intake in the NIH-AARP Diet and Health Study1 
 Nut Intake (n=171,179) Peanut Butter Intake (n=171,523) 
 C1 (n=14,570) C2 (n=51,854) C3 (n=51,537) C4 (n=53,218) C1 (n=38,528) C2 (n=44,279) C3 (n=43,545) C4 (n=45,171) 
Nut or peanut butter intake,  
     g/1000 kcal 
0 0.12 (0.06, 0.19) 0.57 (0.43, 0.77) 2.55 (1.57, 4.64) 0 0.15 (0.09, 0.25) 0.78 (0.54, 1.09) 3.71 (2.41, 6.99) 
Age at baseline, y 63.9 (59.0, 67.3) 63.3 (58.5, 67.0) 62.7 (57.9, 66.6) 63.1 (58.3, 66.8) 63.4 (58.5, 67.0) 62.7 (57.8, 66.7) 63.1 (58.2, 66.8) 63.4 (58.6, 66.9) 
BMI, kg/m2 26.3 (24.1, 29.2) 26.5 (24.3, 29.1) 26.6 (24.5, 29.4) 26.6 (24.4, 29.2) 26.2 (24.2, 28.7) 26.6 (24.4, 29.3) 26.6 (24.4, 29.4) 26.6 (24.4, 29.3) 
Race         
     Non-Hispanic White 93.3 93.7 94.3 93.6 91.8 92.7 94.4 95.7 
     Non-Hispanic Black 2.2 2.2 2.0 2.4 2.2 2.7 2.2 1.7 
     Other 3.3 3.3 2.9 3.2 4.9 3.6 2.5 1.8 
Smoking          
     Never 26.5 29.9 30.3 30.5 30.6 30.0 29.6 29.6 
     Former         
          ≤20 cigarettes/d 26.6 29.2 29.3 29.6 28.4 29.6 29.8 28.7 
          >20 cigarettes/d 31.0 28.2 28.0 28.1 29.7 28.2 27.6 27.9 
     Current         
          ≤20 cigarettes/d 6.6 5.5 5.2 4.9 4.5 5.1 5.5 5.9 
          >20 cigarettes/d 5.3 3.9 3.8 3.8 3.2 3.7 4.2 4.6 
Education, %         
     Less than high school 8.6 5.3 4.3 3.4 4.7 4.6 4.6 4.8 
     Completed high school 29.4 25.5 23.0 20.8 22.0 23.1 24.2 24.9 
     Post-high school or some college 22.2 22.3 22.1 21.5 21.0 21.7 22.7 22.4 
     College and postgraduate 37.0 44.6 48.7 52.5 50.2 48.5 46.4 45.8 
Physical activity, %         
     Never/Rarely 20.4 14.4 13.0 11.8 14.7 13.3 13.5 13.2 
     1-3 times/mo 11.3 13.0 13.2 12.3 11.4 13.2 13.4 12.6 
     1-2 times/wk 17.0 21.4 22.8 22.5 19.6 22.4 22.7 22.1 
     3-4 times/wk 25.9 28.6 29.3 30.0 28.2 28.9 29.3 29.4 
     ≥5 times/wk 24.8 22.0 21.3 22.9 25.3 21.7 20.5 22.1 
Calories, kcal/d 1730 (1305, 2279) 1799 (1391, 2296) 1885 (1448, 2447) 1951 (1547, 2484) 1746 (1346, 2247) 1959 (1486, 2456) 1734 (1409, 2277) 2015 (1563, 2517) 
Vegetable intake, servings/d 3.2 (2.1, 4.9) 3.4 (2.3, 4.8) 3.6 (2.4, 5.1) 3.7 (2.6, 5.3) 3.5 (2.3, 5.1) 3.6 (2.5, 5.2) 3.4 (2.3, 4.8) 3.6 (2.4, 5.0) 
Fruit intake, servings/d 2.4 (1.3, 4.0) 2.4 (1.4, 3.8) 2.4 (1.5, 3.8) 2.5 (1.5, 3.9) 2.6 (1.5, 4.1) 2.5 (1.5, 4.0) 2.4 (1.4, 3.7) 2.4 (1.4, 3.7) 
Red meat intake, g/d 49.2 (22.2, 89.2) 58.2 (32.5, 94.9) 66.3 (38.7, 106.2) 67.0 (38.5, 106.4) 51.6 (24.8, 91.1) 64.4 (36.5, 104.2) 63.7 (38.6, 100.9) 68.1 (40.0, 106.5) 
Alcohol, g/d 1.5 (0, 12.2) 3.2 (0.51, 16.5) 4.3 (0.69, 17.2) 5.2 (0.78, 18.7) 4.7 (0.56, 19.2) 4.9 (0.77, 19.7) 3.6 (0.56, 16.0) 2.9 (0.28, 14.2) 
MUFA intake, g/d 18.9 (12.6, 28.2) 21.2 (15.0, 29.6) 23.6 (16.6, 32.9) 26.0 (18.9, 35.6) 19.1 (13.0, 27.5) 23.2 (16.1, 32.1) 22.5 (16.5, 31.1) 27.6 (20.1, 37.1) 
PUFA intake, g/d 11.2 (7.8, 16.2) 12.4 (8.9, 17.1) 13.8 (9.8, 19.0) 15.5 (11.3, 21.1) 11.5 (8.1, 16.2) 13.6 (9.6, 18.6) 13.2 (9.7, 18.2) 16.1 (11.8, 21.5) 
HEI 2010 65.1 (55.7, 72.6) 65.5 (57.0, 72.6) 65.9 (58.0, 72.6) 68.2 (60.8, 74.7) 66.5 (58.0, 73.5) 65.5 (57.1, 72.4) 66.1 (58.2, 72.7) 67.9 (60.3, 74.4) 
Self-reported history, %         
     Heart disease 26.3 19.1 16.3 15.0 20.7 16.5 17.2 16.5 
     Diabetes 13.5 9.0 9.0 9.8 9.8 8.2 9.4 11.1 
     Stroke  3.4 2.2 1.8 1.7 2.3 1.9 1.9 2.1 
     Hypertension 45.2 41.2 40.1 38.5 41.9 40.8 40.3 38.8 
Screening, % 84.3 87.0 87.8 88.1 87.4 87.4 87.6 87.0 
Prostate cancer family history, % 7.1 8.3 8.5 8.7 7.8 8.4 8.6 8.7 
NOTE: Some percentages do not sum to 100 due to missing data and rounding. 
1 Values are presented as either median (IQR) or percentages. Intake density is based on gram per 1000 kcal. C, category. HEI 2010, Healthy Eating Index 2010. 
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TABLE 2 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut intake (N=171,179)1 
 Nut Intake 
 
C1 C2 C3 C4 P for trend2 
Continuous (every quarter 
cup, or 32.75 g/1000 kcal) 
Median nut intake, g/1000 kcal 0 0.12 0.57 2.55 
  
Person-years, n 162,143 601,356 602,350 624,987   
Overall       
     Cases (n) 1,390 5,667 5,654 5,707   
     Age-Adjusted HR (95% CI)3 1 1.11 (1.05, 1.18) 1.12 (1.06, 1.19) 1.08 (1.02, 1.14) 0.41 0.99 (0.99, 1.00) 
     Multivariable-Adjusted HR (95% CI)4  1 1.05 (0.99, 1.11) 1.05 (0.99, 1.11) 1.00 (0.95, 1.07) 0.04 0.99 (0.98, 1.00) 
Localized       
     Cases (n) 129 476 488 482   
     Age-Adjusted HR (95% CI)3 1 0.96 (0.79, 1.17) 0.98 (0.81, 1.19) 0.93 (0.77, 1.13) 0.44 0.98 (0.96, 1.01) 
     Multivariable-Adjusted HR (95% CI)4  1 0.87 (0.72, 1.06) 0.88 (0.72, 1.07) 0.83 (0.68, 1.01) 0.18 0.99 (0.96, 1.01) 
Advanced       
     Cases (n) 146 618 629 637   
     Age-Adjusted HR (95% CI)3 1 1.15 (0.96, 1.38) 1.18 (0.99, 1.42) 1.14 (0.95, 1.37) 0.86 1.00 (0.98, 1.02) 
     Multivariable-Adjusted HR (95% CI)4  1 1.11 (0.92, 1.33) 1.13 (0.94, 1.36) 1.09 (0.90, 1.30) 0.84 1.00 (0.98, 1.02) 
Fatal       
     Cases (n) 73 211 211 235   
     Age-Adjusted HR (95% CI)3 1 0.81 (0.62, 1.06) 0.84 (0.65, 1.10) 0.88 (0.68, 1.15) 0.68 1.01 (0.97, 1.04) 
     Multivariable-Adjusted HR (95% CI)4  1 0.84 (0.64, 1.11) 0.89 (0.68, 1.17) 0.93 (0.71, 1.22) 0.50 1.01 (0.97, 1.04) 
1 Intake density is based on gram per 1000 kcal. C, category.  
2 Median was used to assess linear trend. 
3 Age-adjusted model adjusted for age (years). 
4 Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school, 
completed high school, post high school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20 
cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) , physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week, 
≥5 times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health (excellent/very good, good, poor/fair), cardiovascular disease, 
marital status, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and alcohol intake (continuous). 
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TABLE 3 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with peanut butter intake (N=171,523)1 
 Peanut Butter Intake 
 
C1 C2 C3 C4 P for trend2 
Continuous (every 1 
tablespoon, or 16 g/1000 kcal) 
Median nut intake, g/1000 kcal 0 0.15 0.78 3.71 
  
Person-years, n 448,342 520,013 505,046 520,897   
Overall       
     Cases (n) 4,055 4,842 4,703 4,850   
     Age-Adjusted HR (95% CI)3 1 1.04 (1.00, 1.09) 1.04 (0.99, 1.08) 1.03 (0.98, 1.07) 0.93 0.96 (0.90, 1.02) 
     Multivariable-Adjusted HR (95% CI)4 1 1.03 (0.98, 1.07) 1.02 (0.98, 1.07) 1.02 (0.98, 1.07) 0.77 0.97 (0.91, 1.03) 
Localized       
     Cases (n) 357 415 407 401   
     Age-Adjusted HR (95% CI)3 1 0.99 (0.86, 1.14) 1.01 (0.88, 1.17) 0.97 (0.84, 1.12) 0.60 0.99 (0.80, 1.23) 
     Multivariable-Adjusted HR  
 (95% CI)4 
1 0.98 (0.85, 1.13) 0.99 (0.86, 1.15) 0.96 (0.83, 1.11) 0.62 1.01 (0.82, 1.26)  
Advanced       
     Cases (n) 431 551 500 555   
     Age-Adjusted HR (95% CI)3 1 1.12 (0.99, 1.27) 1.04 (0.91, 1.18) 1.11 (0.97, 1.25) 0.37 1.01 (0.84, 1.21) 
     Multivariable-Adjusted HR (95% CI)4 1 1.10 (0.97, 1.25) 1.02 (0.89, 1.16) 1.09 (0.96, 1.24) 0.41 1.02 (0.84, 1.23) 
Fatal       
     Cases (n) 158 187 182 205   
     Age-Adjusted HR (95% CI)3 1 1.07 (0.86, 1.32) 1.04 (0.84, 1.29) 1.11 (0.90, 1.37) 0.39 1.05 (0.77, 1.41) 
     Multivariable-Adjusted HR (95% CI)4 1 1.04 (0.84, 1.29) 1.00 (0.81, 1.24) 1.08 (0.88, 1.34) 0.46 1.05 (0.77, 1.42) 
1 Intake density is based on gram per 1000 kcal. C, category.  
2 Median was used to assess linear trend. 
3 Age-adjusted model adjusted for age (years). 
4 Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school, 
completed high school, post high school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20 
cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) , physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week, ≥5 
times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health (excellent/very good, good, poor/fair), cardiovascular disease, marital 




Table 4 Hazard ratios and 95% confidence intervals for risk of prostate cancer according to total nut intake1 
 Total Nut Intake 
 C1 C2 C3 C4 P for trend2 
Person-years, n 80,841 632,269 632,815 633,335  
Overall      
     Cases (n) 700 5,920 5,861 5,840  
     Age-Adjusted HR (95% CI)3 1 1.09 (1.01, 1.18) 1.09 (1.00, 1.17) 1.07 (0.99, 1.15) 0.20 
     Multivariable-Adjusted HR (95% CI)4  1 1.03 (0.96, 1.12) 1.02 (0.95, 1.11) 1.00 (0.93, 1.09) 0.09 
Localized      
     Cases (n) 71 506 508 486  
     Age-Adjusted HR (95% CI)3 1 0.89 (0.70, 1.15) 0.89 (0.70, 1.14) 0.86 (0.67, 1.10) 0.47 
     Multivariable-Adjusted HR (95% CI)4  1 0.82 (0.64, 1.05) 0.80 (0.62, 1.03) 0.77 (0.60, 0.99) 0.36 
Advanced      
     Cases (n) 63 656 631 673  
     Age-Adjusted HR (95% CI)3 1 1.34 (1.04, 1.74) 1.30 (1.00, 1.68) 1.36 (1.05, 1.76) 0.59 
     Multivariable-Adjusted HR (95% CI)4  1 1.26 (0.97, 1.63) 1.21 (0.93, 1.57) 1.27 (0.98, 1.65) 0.64 
Fatal      
     Cases (n) 29 222 239 236  
     Age-Adjusted HR (95% CI)3 1 1.02 (0.69, 1.49) 1.11 (0.75, 1.63) 1.06 (0.72, 1.56) 0.88 
     Multivariable-Adjusted HR (95% CI)4  1 0.99 (0.67, 1.46) 1.08 (0.73, 1.59) 1.04 (0.70, 1.54) 0.80 
1 Intake density is based on gram per 1000 kcal. Q, quartile.  
2 Median was used to assess linear trend. 
3 Age-adjusted model adjusted for age (years). 
4 Multivariable model adjusted for age (years), BMI (kg/m2), calories (kcal/day), education, smoking status, physical activity, race, 
self-reported health, cardiovascular disease, marriage, prostate cancer screening, family history of prostate cancer and vegetable, fruit, 




Table 5 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut consumption frequency 
 Nut Frequency 
 C1 C2 C3 C4 P for trend 
Frequency 
Never to 1-6 
times per year 
7-11 times per year 
to 1 time per month 
2-3 times per month to 
1-2 times per week 
3-4 times per week to 
2+ times per day 
 
Person-years, n 608,146 597,366 615,392 184,167  
Overall Prostate Cancer      
     Cases (n) 5,483 5,616 5,783 1,663  
     Age-Adjusted HR (95% CI)1 1 1.06 (1.02, 1.10) 1.05 (1.01, 1.09) 0.98 (0.93, 1.04) 0.50 
     Multivariable-Adjusted HR (95% CI)2 1 1.03 (0.99, 1.07) 1.00 (0.96, 1.04) 0.93 (0.88, 0.98) 0.07 
Localized Prostate Cancer      
     Cases (n) 484 470 481 148  
     Age-Adjusted HR (95% CI) 1 1 0.97 (0.86, 1.10) 0.97 (0.85, 1.10) 1.00 (0.83, 1.20) 0.80 
     Multivariable-Adjusted HR (95% CI)2 1 0.93 (0.82, 1.06) 0.92 (0.81, 1.05) 0.94 (0.78, 1.14) 0.28 
Advanced      
     Cases (n) 594 620 649 181  
     Age-Adjusted HR (95% CI) 1 1 1.08 (0.96, 1.20) 1.08 (0.97, 1.21) 0.98 (0.83, 1.16) 0.58 
     Multivariable-Adjusted HR (95% CI)2 1 1.05 (0.94, 1.18) 1.04 (0.93, 1.17) 0.93 (0.78, 1.10) 0.84 
Fatal      
     Cases (n) 242 205 211 77  
     Age-Adjusted HR (95% CI) 1 1 0.90 (0.75, 1.09) 0.88 (0.73, 1.06) 1.00 (0.77, 1.29) 0.46 
     Multivariable-Adjusted HR (95% CI)2 1 0.92 (0.76, 1.11) 0.91 (0.75, 1.10) 1.03 (0.79, 1.35) 0.72 
1 Age-adjusted model adjusted for age (years). 
2 Multivariable model adjusted for age (years), BMI (kg/m2), calories (kcal/day), education, smoking status, physical activity, race, self-




SUPPLEMENTAL TABLE 1 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut and peanut butter consumption after exclusion of first 2 
years of follow-up1 
 Nut Intake Peanut Butter Intake 
 C1 C2 C3 C4 C1 C2 C3 C4 
Person-years, n 133,619 499,636 501,033 520,409 372,693 432,985 419,562 432,252 
Overall         
     Cases (n) 1,222 5,029 5,060 5,090 3,597 4,299 4,182 4,354 
     Age-Adjusted HR (95% CI)2 1 1.11 (1.05, 1.18) 1.13 (1.06, 1.20) 1.08 (1.02, 1.15) 1 1.04 (1.00, 1.09) 1.04 (0.99, 1.08) 1.04 (0.99, 1.09) 
     Multivariable-Adjusted HR (95% CI)3 1 1.04 (0.98, 1.11) 1.05 (0.99, 1.12) 1.01 (0.94, 1.07) 1 1.02 (0.98, 1.07) 1.02 (0.98, 1.07) 1.03 (0.99, 1.08) 
Localized         
     Cases (n) 129 476 488 482 357 415 407 401 
     Age-Adjusted HR (95% CI)2 1 0.96 (0.79, 1.17) 0.98 (0.81, 1.19) 0.93 (0.77, 1.13) 1 0.99 (0.86, 1.14) 1.01 (0.88, 1.17) 0.97 (0.84, 1.12) 
     Multivariable-Adjusted HR (95% CI)3  1 0.87 (0.72, 1.06) 0.88 (0.72, 1.07) 0.83 (0.68, 1.01) 1 0.98 (0.85, 1.13) 0.99 (0.86, 1.15) 0.96 (0.83, 1.11) 
Advanced         
     Cases (n) 127 545 571 567 391 486 443 498 
     Age-Adjusted HR (95% CI)2 1 1.16 (0.95, 1.40) 1.22 (1.01, 1.48) 1.16 (0.96, 1.40) 1 1.09 (0.95, 1.24) 1.01 (0.88, 1.16) 1.09 (0.96, 1.25) 
     Multivariable-Adjusted HR (95% CI)3  1 1.11 (0.91, 1.34) 1.16 (0.96, 1.41) 1.09 (0.90, 1.33) 1 1.07 (0.93, 1.22) 1.00 (0.87, 1.15) 1.08 (0.95, 1.24) 
Fatal         
     Cases (n) 59 164 183 194 132 151 151 169 
     Age-Adjusted HR (95% CI)2 1 0.77 (0.57, 1.04) 0.89 (0.67, 1.20) 0.89 (0.67, 1.19) 1 1.03 (0.81, 1.30) 1.03 (0.82, 1.30) 1.10 (0.87, 1.38) 
     Multivariable-Adjusted HR (95% CI)3  1 0.80 (0.59, 1.08) 0.93 (0.69, 1.26) 0.93 (0.69, 1.25) 1 1.00 (0.79, 1.27) 1.01 (0.80, 1.28) 1.08 (0.85, 1.36) 
1 Intake density is based on gram per 1000 kcal. C, category. 
2 Age-adjusted model adjusted for age (years). 
3 Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school, completed high school, post high 
school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20 cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) , 
physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week, ≥5 times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health 
(excellent/very good, good, poor/fair), cardiovascular disease, marital status, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and alcohol intake 
(continuous). 
 
 
